News

The U.S. Food and Drug Administration's reviewers on Wednesday raised efficacy concerns over the use of Otsuka Pharma's drug ...
The FDA staffers on Wednesday cited efficacy issues related to a combination regimen involving brexpiprazole, an ...
The FDA is raising efficacy questions over Lundbeck and Otsuka’s proposed combination of their Rexulti with Viatris’ Zoloft ...
An FDA advisory panel will meet July 18 to consider a supplemental new drug application for the antipsychotic brexpiprazole, ...
Fort Worth's Modern Art Museum hosts "HERE. IS. BETTER.," a PTSD-focused documentary screening. Admission is free with online ...
A woman said she felt "robbed" of her birth experience after a "painful" and "traumatic" delivery left her with ...
The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to TSND-201 (methylone) for the treatment of posttraumatic stress disorder (PTSD).
The tool can help overcome barriers to diagnosis, like cognitive development, language skills, avoidance behaviors and ...
A new study found active-duty service members with sleep apnea face a greater risk of PTSD or a traumatic brain injury, ...